- Report
- January 2026
- 183 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- January 2026
- 191 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- January 2026
- 184 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- January 2026
- 199 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- January 2026
- 193 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- August 2025
- 180 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- August 2025
- 192 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- August 2025
- 188 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- August 2025
- 191 Pages
Global
From €3423EUR$3,939USD£2,979GBP
- Report
- August 2025
Global
From €4259EUR$4,900USD£3,706GBP
- Report
- July 2025
Global
From €4259EUR$4,900USD£3,706GBP
- Report
- June 2025
- 120 Pages
Global
From €4259EUR$4,900USD£3,706GBP
- Report
- April 2025
Global
From €4259EUR$4,900USD£3,706GBP
- Report
- October 2025
Global
From €4259EUR$4,900USD£3,706GBP
- Report
- May 2025
- 100 Pages
Global
From €4259EUR$4,900USD£3,706GBP
From €4259EUR$4,900USD£3,706GBP
- Report
- September 2025
- 250 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- September 2025
- 250 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- July 2025
- 175 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- July 2025
- 175 Pages
Global
From €3902EUR$4,490USD£3,396GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more